<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961857</url>
  </required_header>
  <id_info>
    <org_study_id>0431A-048</org_study_id>
    <secondary_id>MK0431A-048</secondary_id>
    <secondary_id>2009_635</secondary_id>
    <nct_id>NCT00961857</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)</brief_title>
  <official_title>An Open-label, Randomized Two-Part, Two-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of Final Market Image (FMI) Sitagliptin /Metformin 50/500 mg and 50/1000 mg Fixed Dose Combination (FDC) and Concomitant Administration of 50 mg Doses of Sitagliptin and 500 or 1000 mg Doses of Metformin as Individual Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-part study to demonstrate the bioequivalence of a single dose of the Final Market Image
      (FMI) of sitagliptin /metformin (50/500 and 50/1000 mg) Fixed-Dose Combination (FDC) tablet
      and co-administration of a single dose of sitagliptin (50 mg) and metformin ( 500 or 1000 mg)
      as individual tablets. Subject will only participate in one part, receiving treatment A and B
      (Part I) or Treatment C and D (Part II).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration vs. time curve (AUC) after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of sitagliptin and metformin after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets</measure>
    <time_frame>72 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual Tablets of 50 mg sitagliptin and 500 mg metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin/metformin 50 mg/500 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual Tablets of 50 mg sitagliptin and 1000 mg metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin/metformin 50 mg/1000 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate (+) metformin hydrochloride</intervention_name>
    <description>place holder - do not post</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: metformin 500 mg</intervention_name>
    <description>A single dose of metformin 500 mg tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Apotex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: sitagliptin</intervention_name>
    <description>A single 50 mg tablet of sitagliptin</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet</intervention_name>
    <description>A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet</intervention_name>
    <description>A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: metformin 1000 mg</intervention_name>
    <description>A single dose of metformin 1000 mg tablets</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Apotex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of reproductive potential test negative for pregnancy and agree to use
             appropriate contraception

          -  Subject is in good health and is a non-smoker

          -  Subject is willing to avoid strenuous physical activity during the study

          -  Subject agrees to refrain from eating grapefruit or grapefruit products during the
             study

        Exclusion Criteria:

          -  Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or
             major neurological disorder. Subject has a history of clinically significant
             endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological,
             renal, respiratory, or genitourinary abnormalities or diseases

          -  Subject consumes excessive amounts of alcohol or caffeinated beverages

          -  Subject has donated blood, had surgery or participated in another clinical study
             within the past 4 weeks

          -  Subject has a history of significant multiple and/or severe allergies to prescription
             or non-prescription drugs or food

          -  Subject has a history of hypersensitivity to metformin, sitagliptin, or
             sitagliptin/Metformin

          -  Subject is a regular user or past abuser of any illicit drugs

          -  Subject is unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs or herbal remedies during the study.

          -  Subject is a nursing mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

